US pharma to build €2.6B obesity drug plant in Dutch village, local unrest

A US company announced a €2.6 billion factory for obesity drugs in Valkenburg, Netherlands, celebrated in The Hague but causing local concern. The investment signals major pharma commitment to GLP-1 production, but local opposition could delay construction. This is a significant corporate investment with potential economic and political implications.